[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335763-105":59,"doc-detail-335763-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-immune-landscape-and-its-potential-for-immunotherapy-in-advanced-biliary-tract-cancer","The Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer","","Biliary tract cancers (BTC) form a highly heterogeneous group across genomic, epigenetic, and molecular dimensions, with most patients presenting at an advanced unresectable stage because symptoms are limited and tumor biology is aggressive. Chemotherapy remains the main treatment, yet outcomes and prognosis are poor. Adding immune checkpoint inhibitors (ICI) to chemotherapy has produced only marginal benefits, reflecting the complex tumor immune microenvironment. This review evaluates current immune landscape knowledge in advanced BTC, including transcriptome-based classifications, immune evasion and resistance mechanisms, therapeutic implications, and emerging biomarkers to predict ICI response.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-immune-landscape-and-its-potential-for-immunotherapy-in-advanced-biliary-tract-cancer/335763/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-immune-landscape-and-its-potential-for-immunotherapy-in-advanced-biliary-tract-cancer/335763.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do most patients with biliary tract cancers present with advanced unresectable disease?","Question",{"text":112,"@type":113},"Most patients present at an advanced stage due to limited early detection, challenging anatomical access, and aggressive tumor biology.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the role of immune checkpoint inhibitors in advanced biliary tract cancer?",{"text":117,"@type":113},"ICI aim to restore immune function by blocking inhibitory checkpoints such as PD-1, PD-L1, and CTLA-4, and are used in combination with chemotherapy.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is the survival benefit of combining ICI with chemotherapy often marginal?",{"text":121,"@type":113},"The review attributes the limited magnitude of benefit to the complex tumor immune microenvironment of BTC, which drives immune evasion and resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335763,1790016156,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Review  \nThe Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer  \nAndry Santoso 1,†, Iris Levink 1,2,†, Rille Pihlak 3 and Ian Chau 1, *  \nReceived: 14 November 2024  \nRevised: 19 December 2024  \nAccepted: 25 December 2024  \nPublished: 31 December 2024  \nCitation: Santoso, A.; Levink, I.; Pihlak, R.; Chau, I. The Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer. Curr. Oncol. 2025, 32, 24 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)curroncol32010024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Gastrointestinal Unit, The Royal Marsden Hospital, London SW3 6JJ, UK; [andry.santoso@rmh.nhs.uk](andry.santoso@rmh.nhs.uk) (A.S.); [i.levink@erasmusmc.nl](i.levink@erasmusmc.nl) (I.L.)  \n2 Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, 3015 GD Rotterdam, The Netherlands  \n3 University Hospitals Sussex NHS Foundation Trust, Brighton BN1 9RW, UK; [rille.pihlak@nhs.net](rille.pihlak@nhs.net)  \n* Correspondence: [ian.chau@rmh.nhs.uk](ian.chau@rmh.nhs.uk); Tel.: +44-02073528171 † These authors contributed equally to this work.  \nAbstract: Biliary tract cancers (BTC) are a highly heterogeneous group of cancers at the genomic, epigenetic and molecular levels. The vast majority of patients initially present at an advanced (unresectable) disease stage due to a lack of symptoms and an aggressive tumour biology. Chemotherapy has been the mainstay of treatment in patients with advanced BTC but the survival outcomes and prognosis remain poor. The addition of immune checkpoint inhibitors (ICI) to chemotherapy have shown only a marginal benefit over chemotherapy alone due to the complex tumour immune microenvironment of these cancers. This review appraises our current understanding of the immune landscape of advanced BTC, including emerging transcriptome-based classifications, highlighting the mechanisms of immune evasion and resistance to ICI and their therapeutic implications. It describes the shifting treatment paradigm from traditional chemotherapy to immunotherapy combinations as well as the potential biomarkers for predicting response to ICI.  \nKeywords: cholangiocarcinoma; biliary tract cancer; immune microenvironment; immunotherapy  \n1. Introduction  \nBiliary tract cancers (BTC) are a highly heterogeneous group of malignant tumours which include true cholangiocarcinoma (CCA), gall bladder carcinoma (GBC) and sometimes ampullary carcinoma. CCAs can be divided into intrahepatic cholangiocarcinoma (iCCA), accounting for 10–20% of CCAs, and extra-hepatic cholangiocarcinoma (eCCA), the latter of which is further divided into peri-hilar carcinoma (pCCA), accounting for 50–60% of CCAs, and distal carcinoma (dCCA), accounting for 20–30% of CCAs [1,2] . These subtypes of BTC differ not only in their anatomical location, but also in their clinical presentation, genetics and molecular drivers [3] .  \nBTCs arise from cholangiocytes, hepatocytes, hepatic stem cells and the peribiliary glands located in the lining of bile ducts [4] . Whilst several genetic mutations, epigenetic alterations and factors in the microenvironment have been uncovered, the full aetiology of BTC and the role of the immune system remains unresolved. It is implicated that tumorigenesis can be triggered by liver diseases characterised by a high inflammatory state. These include infectious diseases (such as liver fluke and hepatitis), cholelithiasis, metabolic-associated fatty liver disease, alcoholic liver disease and liver damage from drugs and smoking [5–7] . These conditions have high concentrations of inflammatory mediators that are released a","cbCaijulpXHQftI3","https://ap.wps.com/l/cbCaijulpXHQftI3","pdf",1031086,"English","# Introduction\n# Immune checkpoint inhibitors and treatment paradigm\n# Immune landscape in advanced biliary tract cancer\n# Mechanisms of immune evasion and resistance\n# Transcriptome-based classification\n# Biomarkers for predicting ICI response","[{\"question\":\"Why do most patients with biliary tract cancers present with advanced unresectable disease?\",\"answer\":\"Most patients present at an advanced stage due to limited early detection, challenging anatomical access, and aggressive tumor biology.\"},{\"question\":\"What is the role of immune checkpoint inhibitors in advanced biliary tract cancer?\",\"answer\":\"ICI aim to restore immune function by blocking inhibitory checkpoints such as PD-1, PD-L1, and CTLA-4, and are used in combination with chemotherapy.\"},{\"question\":\"Why is the survival benefit of combining ICI with chemotherapy often marginal?\",\"answer\":\"The review attributes the limited magnitude of benefit to the complex tumor immune microenvironment of BTC, which drives immune evasion and resistance.\"}]","The Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer | PDF",1790012240]